Drugs / ONC-841
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06352359 | Aug 2024 → Sep 2027 expected | — | OncoC4, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06219499 | Jun 2024 → Jun 2025 | — | OncoC4, Inc. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-07-28 | OncoC4, Inc. | Results OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease oncoc4.com ↗
OncoC4, Inc., a late-stage biopharmaceutical company focused on developing novel medicines for cancer, today unveiled new preclinical data that highlight the potential of ONC-841, a novel immune checkpoint inhibitor, in treating Alzheimer’s disease (AD). |
| 2024-04-23 | OncoC4, Inc. | Regulatory OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors oncoc4.com ↗
OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced that the United States Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for ONC-841, a potential first-in-class SIGLEC 10 blocking antibody for the treatment of solid tumors. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONC-841 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06219499 ↗ |
| Action | Inhibit | “ONC-841 binds to Siglec10 to block the "do not eat me" signals” NCT06352359 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT06219499 ↗ |
| Route | Intravenous | “When Administered Intravenously” NCT06219499 ↗ |